Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
基本信息
- 批准号:10667563
- 负责人:
- 金额:$ 52.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalActivinsAdhesionsAdvanced Glycosylation End ProductsAgingAnatomyBiologicalCell modelCellsCessation of lifeClinical ManagementCollaborationsCollagenCommunicationDNA DamageDataDetectionDevelopmentDevicesEngineeringEpithelial CellsEpitheliumExposure toFallopian Tube NeoplasmsFollicular FluidGelGrantHomingHormonesHumanImaging technologyLesionLiteratureLocationMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMammalian OviductsMenarcheMenstrual cycleMetastatic Malignant Neoplasm to the OvaryMicrofluidic MicrochipsMicrofluidicsModelingMonitorNamesNational Institute of Environmental Health SciencesNatureNeoplasm MetastasisOperative Surgical ProceduresOral ContraceptivesOrganOvarianOvarian FollicleOvaryOvulationPaperPathway interactionsPeritonealPeritoneal FluidPhysiologicalPhysiological ProcessesPregnancyProcessProtein SecretionProteinsReactive Oxygen SpeciesRepressionResearch SupportRiskRisk FactorsRisk ReductionRoleSamplingSerousSignal TransductionSiteSourceSurfaceSystemTechnologyTestingTissue MicroarrayTissuesTransforming Growth Factor betaTransgenic MiceTubal ExcisionsTubal LigationTumor Cell MigrationTumor ExpansionXenograft procedurecancer diagnosiscancer stem cellcarcinogenesisdesignfemale reproductive systemhigh riskhuman tissuein vivoinventionmigrationmortalitymouse modelneoplasticneoplastic cellnewsnoveloptical imagingovulation timepreneoplastic cellpreventreproductiveresponsesmall moleculestem cell biomarkersthree dimensional cell culturetumortumor initiationtumorigenesisversican
项目摘要
Ovarian cancer is the most lethal cancer of the female reproductive system, with over 21,000 new ovarian
cancer diagnoses and 14,000 deaths annually in the US. The menstrual cycle, specifically the total lifetime
number of ovulations, is a key risk factor for developing ovarian cancer. Factors that repress ovulation reduce
the risk of ovarian cancer, such as oral contraceptives, pregnancy, and late menarche. The most common and
deadly histotype of ovarian cancer, termed high grade serous cancer (HGSC), likely originates from the
fallopian tube epithelial cells, and not the ovary. The frequent detection of tumors in the ovary, which resulted
in the name “ovarian cancer”, suggests that the ovary provides a unique anatomical location for tumor
migration and expansion. Since most research supports that the fallopian tube is the source of ovarian cancer,
it becomes critical to understand how ovulation contributes to tumor initiation in this site. Our team developed
three-dimensional organotypic cultures supported in a state-of-the-art microfluidic platform that supports the
ovary to produce dynamic hormone profiles that closely mimic the 28-day human reproductive menstrual cycle
and ovulation on platform. The device was one of the C&E News Top 10 Inventions of 2017 and our paper in
Nature Communications was the top NIEHS paper of 2017. The proposal will build on this successful
collaboration to expand our technology and models to studying the role of the ovary in fallopian tube
carcinogenesis and metastasis. Our hypothesis is that the microenvironment of the ovary contributes to
tumor initiation, migration, and tumor cell expansion of high grade serous cancers derived from
fallopian tube. Aim 1 will integrate our 3D culture of the ovary and models of the fallopian tube in a new
PREDICT96 microfluidic device to define the how the physiological process of ovulation, specifically follicular
fluid, drives fallopian tube tumor initiation using primary human fallopian tube samples, preneoplastic cell
models, tumor models, and a transgenic mouse model developed in the Burdette lab. In Aim 2, we will validate
the role of the secreted protein, versican, from the 3D ovary that enhances fallopian tube homing to the ovary
and we will test small molecules for their ability to block ovarian colonization using 3D ex vivo microfluidic
models and in vivo. In Aim 3, we will investigate the mechanisms responsible for tumor cell escape from the
fallopian tube, which we hypothesize is due to spheroid formation and the colonization of exposed three-
dimensional collagen in the ovary at sites of ovulation. Overall, this grant will employ unique devices, primary
human tissues, and three dimensional preneoplastic and tumor models to unveil new biological targets in an
effort to reduce tumor initiation and spread of fallopian derived high grade serous cancer in the ovarian
microenvironment.
卵巢癌是女性生殖系统中最致命的癌症,有21,000多个新卵巢癌
在美国,癌症诊断和14,000例死亡。月经周期,特别是总寿命
排卵的数量是发展卵巢癌的关键危险因素。反映排卵的因素减少
卵巢癌的风险,例如口服避孕药,妊娠和初潮晚期。最常见的
卵巢癌的致命组织型,称为高级浆液癌(HGSC),可能起源于
输卵管上皮细胞,而不是卵巢。经常检测到卵巢中的肿瘤,这导致
在“卵巢癌”的名称中,卵巢为肿瘤提供了独特的解剖位置
迁移和扩张。由于大多数研究都支持输卵管是卵巢癌的来源,所以
了解排卵如何有助于该站点的肿瘤创新,这变得至关重要。我们的团队发展了
在最先进的微流体平台上支持的三维有机文化,该平台支持
卵巢产生动态的骑马曲线,这些曲烯轮廓非常模仿28天的人类复制月经周期
和平台上的排卵。该设备是2017年C&E新闻十大发明之一,我们的论文
自然通讯是2017年NIEHS的顶级论文。该提案将以这一成功为基础
合作以扩展我们的技术和模型,以研究卵巢在输卵管中的作用
癌变和转移。我们的假设是卵巢的微环境有助于
高级浆液癌的肿瘤起始,迁移和肿瘤细胞扩张
输卵管。 AIM 1将在一个新的
预测96微流体设备,以定义排卵的物理过程,特别是卵泡
流体,使用原发性人输卵管样品,产前塑性细胞驱动输卵管肿瘤倡议
模型,肿瘤模型和Burdette实验室中开发的转基因小鼠模型。在AIM 2中,我们将验证
分泌的蛋白质,versican的作用,从3D卵巢增强了输卵管归巢为卵巢
我们将测试小分子使用3D EX VIVO微流体来阻断卵巢定殖的能力
模型和体内。在AIM 3中,我们将研究导致肿瘤细胞逃脱的机制
输卵管,我们假设是由于球体的形成和暴露的三个 -
排卵部位的卵巢中的尺寸胶原蛋白。总体而言,该赠款将采用独特的设备,主要设备
人体组织以及三维前塑性和肿瘤模型,以揭示新的生物学靶标
努力减少输卵管衍生的高级浆液癌的肿瘤倡议和卵巢的传播
微环境。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Increased Local Testosterone Levels Alter Human Fallopian Tube mRNA Profile and Signaling.
- DOI:10.3390/cancers15072062
- 发表时间:2023-03-30
- 期刊:
- 影响因子:5.2
- 作者:
- 通讯作者:
Silencing PTEN in the fallopian tube promotes enrichment of cancer stem cell-like function through loss of PAX2.
- DOI:10.1038/s41419-021-03663-2
- 发表时间:2021-04-07
- 期刊:
- 影响因子:9
- 作者:Russo A;Colina JA;Moy J;Baligod S;Czarnecki AA;Varughese P;Lantvit DD;Dean MJ;Burdette JE
- 通讯作者:Burdette JE
The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research.
- DOI:10.1158/2767-9764.crc-22-0017
- 发表时间:2022-06
- 期刊:
- 影响因子:0
- 作者:Rodriguez GM;Galpin KJC;Cook DP;Yakubovich E;Maranda V;Macdonald EA;Wilson-Sanchez J;Thomas AL;Burdette JE;Vanderhyden BC
- 通讯作者:Vanderhyden BC
Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
卵巢分泌的多功能蛋白聚糖与输卵管衍生浆液性癌的排卵和迁移有关。
- DOI:10.1016/j.canlet.2022.215779
- 发表时间:2022-09-01
- 期刊:
- 影响因子:9.7
- 作者:Russo, Angela;Yang, Zizhao;Heyrman, Georgette Moyle;Cain, Brian P.;Carrero, Alfredo Lopez;Isenberg, Brett C.;Dean, Matthew J.;Coppeta, Jonathan;Burdette, Joanna E.
- 通讯作者:Burdette, Joanna E.
Reply: Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating.
答复:人类输卵管上皮暴露于升高的睾酮会导致纤毛基因表达和跳动的改变。
- DOI:10.1093/humrep/deab022
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Jackson-Bey,Tia;Colina,José;Isenberg,BrettC;Coppeta,Jonathan;Urbanek,Margrit;Kim,JJulie;Woodruff,TeresaK;Burdette,JoannaE;Russo,Angela
- 通讯作者:Russo,Angela
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joanna E Burdette其他文献
Joanna E Burdette的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joanna E Burdette', 18)}}的其他基金
Development of quantitative mass spectrometry assays and imaging for cancer metastasis
开发癌症转移的定量质谱分析和成像
- 批准号:
10533035 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
- 批准号:
10055916 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis
研究癌症转移代谢物的成像质谱方法
- 批准号:
10393491 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
- 批准号:
10460287 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis
研究癌症转移代谢物的成像质谱方法
- 批准号:
10737811 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
IRACDA at University of Illinois at Chicago
伊利诺伊大学芝加哥分校 IRACDA
- 批准号:
10672429 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis
研究癌症转移代谢物的成像质谱方法
- 批准号:
10622483 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
- 批准号:
10190857 - 财政年份:2019
- 资助金额:
$ 52.76万 - 项目类别:
Microfluidic Models of Ovarian Cancer Preneoplastic Lesions
卵巢癌癌前病变的微流体模型
- 批准号:
10062680 - 财政年份:2019
- 资助金额:
$ 52.76万 - 项目类别:
Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer
高级别浆液性卵巢癌中卵巢-输卵管轴的动态相互作用
- 批准号:
10425372 - 财政年份:2019
- 资助金额:
$ 52.76万 - 项目类别:
相似国自然基金
电针激活大麻素CB1受体抑制mPFC–LS环路缓解应激性焦虑的机制
- 批准号:82374584
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
印度梨形孢激活根系质子泵促进水稻高效利用土壤磷素的调控机制
- 批准号:42307419
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
DNA甲基化调控ERV激活干扰素免疫及长效抗H3K27M突变型胶质瘤增殖的机制研究
- 批准号:82303064
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
5-甲氧基色胺激活AhR/CXCL14改善肝胰岛素抵抗的作用与机制研究
- 批准号:82370815
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
产酸拟杆菌通过代谢产物N-乙酰血清素激活IDO1-AhR信号介导Treg-巨噬细胞轴减轻脓毒症肝损伤的作用及机制
- 批准号:82330067
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
相似海外基金
Decoding the non-binary signaling logic that controls cell fate
解码控制细胞命运的非二进制信号逻辑
- 批准号:
10028739 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Decoding the non-binary signaling logic that controls cell fate
解码控制细胞命运的非二进制信号逻辑
- 批准号:
10794428 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Decoding the non-binary signaling logic that controls cell fate
解码控制细胞命运的非二进制信号逻辑
- 批准号:
10809086 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Decoding the non-binary signaling logic that controls cell fate
解码控制细胞命运的非二进制信号逻辑
- 批准号:
10204060 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别:
Decoding the non-binary signaling logic that controls cell fate
解码控制细胞命运的非二进制信号逻辑
- 批准号:
10404957 - 财政年份:2020
- 资助金额:
$ 52.76万 - 项目类别: